as patient age, histologic grade, hormone receptor status and c-erbB-2 status did not have independent significance in IBC in this study.
Inflammatory breast cancer (IBC) is an aggressive form of the disease accounting for 1-5% of all breast cancers [1] . The clinical characteristics of IBC include skin erythema, edema, peau d'orange, tenderness, induration, warmth and enlargement of the breast, and nearly all patients have axillary lymph node involvement at the time of the diagnosis [2, 3] . Pathologically, IBC presents with dermal lymphatic invasion [2] . The management of patients with locally advanced IBC requires a multimodality approach involving systemic chemotherapy, surgery and radiotherapy [4, 5] .
With regards to the clinical course following primary therapy, locally advanced IBC is a heterogeneous disease. Although the prognosis of IBC is poorer when compared with noninflammatory locally advanced breast cancers, there is a minority of the patients who enjoy a longer disease-free survival [1] . Among the prognostic factors ana-lyzed in the few studies focusing on IBC, absence of p53 mutations appeared to predict longer disease-free and overall survival (OS) following primary therapy [6] [7] [8] .
The clinical course of metastatic IBC, however, has not been thoroughly investigated. It is unknown whether the established prognostic markers in metastatic non-IBC have significance in IBC as well. Because IBC is a relatively rare disease, the majority of the available data are derived from small single-arm clinical trials and retrospective reviews and relate to nonmetastatic IBC [5, 6, 8, 9] . The aim of this study was to determine the prognostic markers in metastatic IBC.
Subjects and Methods
A total of 68 consecutive patients with IBC were treated with a curative intent at the Division of Medical Oncology, Ege University School of Medicine, between 1993 and 2002. In all the patients, upfront management consisted of surgery, adjuvant radiotherapy and systemic chemotherapy in a neoadjuvant and/or adjuvant setting and adjuvant hormonal therapy in hormonereceptor-positive patients. The diagnosis of IBC required the presence of erythema, warmth, ridging and peau d'orange appearance of the breast with evidence of dermal lymphatic invasion on pathological evaluation. All patients had baseline assessments of complete blood count, as well as renal and hepatic function tests. Imaging studies before treatment included chest X-ray, abdominal ultrasound and radionuclide bone scan. Computed tomography (CT) scans of the chest, abdomen and pelvis were done when deemed necessary by the treating physician. Chest X-ray, abdominal ultrasound and laboratory studies were repeated every 3 months.
All patients underwent total mastectomy. Except for 1 patient with cardiomyopathy, all patients received an anthracycline-containing regimen either in the neoadjuvant or adjuvant setting. Sixteen patients received neoadjuvant and 44 patients received adjuvant chemotherapy. In the 25 patients, the adjuvant chemotherapy included a taxane. All patients were given adjuvant radiotherapy. Antiestrogen therapy was given to the 21 hormone-receptor-positive patients. A median of 3 chemotherapy regimens (range = 0-7) were administered for metastatic IBC. Chemotherapies in the metastatic setting included docetaxel, paclitaxel, gemcitabine and vinorelbine. In 10 patients, the treatment also included trastuzumab. In 29 patients, first-line chemotherapy included a taxane, while 10 patients had vinorelbine alone or in combination with gemcitabine.
Fifty-seven patients developed metastasis during follow-up. Twelve patients lost to follow-up were excluded. The remaining 45 patients with metastatic IBC were included in this study. Before the initiation of treatment for metastatic IBC, each patient had an ECG, chest X-ray, abdominal ultrasound, and CT scans of the chest and abdomen. Histologic proof of IBC and radiographic evidence of metastatic disease with at least 1 measurable or assessable lesion were required. Medical history, physical examination, Eastern Cooperative Oncology Group performance status and laboratory tests (hematology, blood chemistry) were also obtained. Complete blood counts and serum biochemistry were performed at the beginning of each chemotherapy cycle. Radiological assessments were repeated at 8-to 9-week intervals. Response to treatment was assessed using WHO criteria [10] . Recurrences or metastases were classified as either visceral (lung, liver and other organs) or nonvisceral (lymph node, bone and skin involvement).
Expression of c-erbB-2, p53, Ki-67, ER and PgR was examined by immunohistochemistry. Immunohistochemical studies were performed on histological sections prepared from the biopsy sample taken before treatment. All tissues had been fixed in 4% buff- Cells were considered positive for ER, PgR, p53 and Ki-67 when distinct nuclear staining was identified. A 10% cutoff point was chosen to designate tumor cells as having negative or positive p53 and Ki-67 expressions. Tumor specimens were considered positive for ER/PgR when 6 1% of the cells showed nuclear staining. c-erbB-2 expression was graded as 1+, 2+ or 3+ based on the intensity of staining in 1 10% of the tumor cells. A score of 3+ was used as the cutoff point for overexpression.
OS was defined as the time from the detection of the first metastasis to death. Kaplan Meier and log rank tests were used for the analysis of OS. Multivariate analysis was evaluated by stepwise forward Cox regression analysis. The Fisher exact test was used to assess the significance of association of p53 distribution in patients with visceral or nonvisceral metastasis. SPSS (SPSS Inc., Chicago, Ill., USA) v.11.5 was used for the statistical analysis. Differences in statistical tests were considered as significant when p ^ 0.05.
Results
The patient characteristics are summarized in table 1 . The median age was 43 years (range = 24-82). Twenty-one patients (47%) had c-erbB-2-negative or normal breast cancer, while c-erbB-2 was 3+ in 24 patients (53%) ( fig. 1 A) . ER and/or PR were positive in 21 (47%) and both receptors were negative in 24 patients (53%) ( fig. 1 B) . Twenty-two patients (49%) had Ki-67-negative and 23 (51%) had Ki-67-positive tumors ( fig. 1 C) . p53 expression was positive in 23 patients (51%) and negative in 22 (49%) ( fig. 1 D) .
The objective response rate defined as the sum of complete and partial responses was 33% for first-line chemotherapy. The median progression-free survival following first-line chemotherapy was 8.6 months (range = 1-37).
At a median follow-up of 20 months from the detection of metastatic disease [95% confidence interval (CI) = 16.1-23.9), 13 patients (29%) were alive. The median OS was 23 months (95% CI = 18-28). In the univariate analysis, p53 accumulation and the presence of visceral metastasis were predictive of poor survival (p = 0.01 and 0.003, respectively; table 2 ). In the multivariate analysis, accumulation of p53 protein and the presence of visceral metastasis remained to be the 2 significant predictors of poor OS (p = 0.02, HR = 2.49, 95% CI = 1.13-5.44 and p = 0.008, HR = 3.46, 95% CI = 1.39-8.60, respectively). The median OS for the 22 patients with p53-negativetumors was 43 months. In contrast, the OS for the 23 pa- tients with p53-positive disease was only 17 months (p = 0.01; fig. 2 ). The median OS for patients with visceral disease was 17 months versus 43 months for those without visceral organ involvement (p = 0.003; fig. 3 ). p53 positivity was similar in patients with visceral and nonvisceral metastasis (53 and 47%, respectively, p = 0.75, using Fisher exact test). In patients with visceral disease, the median OS was 15 months for patients with p53-positive tumors and 20 months for patients with p53-negative tumors (p = 0.11). The median OS for patients with p53-positive and p53-negative tumors was 27 months and 43 months, respectively (p = 0.12), in the group with nonvisceral disease. 
Discussion
In this study, it has been shown that p53 protein accumulation and presence of visceral organ involvement are predictors of poor survival in metastatic IBC.
The prevalence of p53 mutations appeared higher in IBC than in nonIBC. In previous studies, p53 mutations had been shown in 30-69% of IBC [6] [7] [8] [9] 11] . In our study, p53 accumulation was seen in 51% of the patients, thereby confirming the prognostic significance of p53 mutations in IBC. As pointed out by Riou et al. [6] , IBC patients with a mutant p53 gene and p53 protein overexpression had an 8.6-fold increased risk of death when compared to the patients with neither gene mutations nor protein overexpression [6] . In this study, the risk of death was found to be even higher when ER was negative in addition to the p53 abnormality.
In this study, p53 protein accumulation was assessed by IHC. This method relies on the detection of the protein encoded by a mutated p53 gene which is not degraded as quickly as the wild-type protein. p53 mutations which generate truncated proteins, like nonsense and splicing mutations, do not correlate well with p53 overexpression by IHC [12] . However, these mutations are rarely observed [13] . Currently, IHC is the most commonly used modality for the evaluation of p53 mutations because sequencing of the p53 gene in all breast cancers would be expensive and time consuming in daily practice. Therefore, p53 determination by IHC as used in this study provides a practical tool to assess prognosis in metastatic IBC.
In studies of metastatic breast cancer, it has been shown that hormone receptor status, performance status, patient age, tumor grade, c-erbB-2 overexpression, number of metastatic sites, visceral metastasis and diseasefree survival are predictors of survival [14] [15] [16] [17] . In our study, presence of visceral metastasis was the only other significant predictor of poor survival. Because of the rarity of the disease, published studies of IBC [5] [6] [7] [8] [9] have been retrospective in nature and have typically involved ! 100 patients. Larger multiinstitutional prospective studies are needed to confirm our observations and determine whether other prognostic markers exist that may have been missed in smaller studies.
One reason for the poor prognosis of p53 mutated IBC may be the relative resistance of p53-positive tumors to chemotherapy, although this issue is a matter of ongoing debate. Studies on p53 mutations and chemosensitivity in breast cancer have produced inconsistent results [18, 19] . Most trials have shown that p53 is a negative predictor of response to anthracyclines [19] [20] [21] [22] [23] . Fewer studies have focused on the predictive value of p53 for response to taxanes. The results of these studies have been inconclusive [24] [25] [26] [27] [28] .
Conclusion
These results indicate that as in noninflammatory metastatic breast cancer, IBC is a heterogeneous disease with regard to prognosis. Patients with p53 protein accumulation and visceral organ involvement appear to have a life expectancy significantly shorter than those without these poor prognostic features. p53 status and presence or absence of visceral metastasis constitute a clinically useful tool to estimate prognosis and for risk stratification in metastatic IBC. However, larger prospective studies will be needed to confirm these findings.
